ReviewAllergy, asthma & immunology research2020
Critical Points on the Use of Biologicals in Allergic Diseases and Asthma.
Review in Allergy, asthma & immunology research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05009758 (Moving Towards PREcision Medicine In United Airways Disease), which is not on this map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Moving Towards PREcision Medicine In United Airways Disease: Unraveling inflaMmatory Patterns in Asthmatic Patients With or Without Nasal Polyps (PREMIUM) - a Descriptive Pilot Study
Who cites it
12 citing papers in PubMed, 28 citations in OpenAlex.
- Endotype-driven decisions in choosing a biologic for airway diseases.Frontiers in allergy · 2025Review
- Eosinophilic-Associated Disease Overlap: What Do We Know About It?Allergy, asthma & immunology research · 2023Article
- Roles of Tissue Inhibitor of Metalloproteinase-1 in Severe Asthma.Allergy, asthma & immunology research · 2023Article
- Emerging Biomarkers Beyond Leukotrienes for the Management of Nonsteroidal Anti-inflammatory Drug (NSAID)-Exacerbated Respiratory Disease.Allergy, asthma & immunology research · 2022Review
- The Korean Severe Asthma Registry (KoSAR): real world research in severe asthma.The Korean journal of internal medicine · 2022Review
- From Emollients to Biologicals: Targeting Atopic Dermatitis.International journal of molecular sciences · 2021Review
- Type II alveolar epithelial cell-specific loss of RhoA exacerbates allergic airway inflammation through SLC26A4.JCI insight · 2021Article
- Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma.The Korean journal of internal medicine · 2021Article
- The Risk of Psoriasis in Patients With Allergic Diseases: A Nationwide Population-based Cohort Study.Allergy, asthma & immunology research · 2021Article
- Pulmonary Surfactants: a New Therapeutic Target in Asthma.Current allergy and asthma reports · 2020Review
- RhoA/Rho-kinases in asthma: from pathogenesis to therapeutic targets.Clinical & translational immunology · 2020Review
- Elevated granulocytic myeloid-derived suppressor cells are closely related with elevation of Th17 cells in mice with experimental asthma.International journal of biological sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Improved understanding of the contribution of immune-inflammatory mechanisms in allergic diseases and asthma has encouraged development of biologicals and small molecules specifically targeting the innate and adaptive immune response. There are several critical points impacting the efficacy of this stratified approach, from the complexity of disease endotypes to the effectiveness in real-world settings. We discuss here how these barriers can be overcome to facilitate the development of implementation science for allergic diseases and asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.